

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 17/11/2015

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
FEXERIC	EMEA/H/C/3776	V03AE	ferric citrate coordination complex	Keryx Biopharma UK Ltd.	lug-15	23-set-15	30-ott-15	16-nov-15	044512010	1
ICLUSIG	EMEA/H/C/PSUSA/10128/201412	L01XE24	ponatinib	ARIAD Pharma Ltd	lug-15	18-set-15	30-ott-15	16-nov-15	042853059	5
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507010	1
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507022	2
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507034	3
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507046	4
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507059	5
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507061	6
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507073	7
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507085	8
INTUNIV	EMEA/H/C/3759	C02AC02	guanfacine	Shire Pharmaceuticals Ireland Limited	lug-15	17-set-15	30-ott-15	16-nov-15	044507097	9
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509014	1
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509026	2
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509038	3
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509053	4
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509065	5
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509077	6
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509089	7
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509091	8
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509115	9
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509127	10
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509139	11
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509141	12
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509154	13
IVABRADINE ANPHARM	EMEA/H/C/4187	C01EB17	ivabradine	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	lug-15	08-set-15	30-ott-15	16-nov-15	044509166	14
PEMETREXED LILLY	EMEA/H/C/4114	L01BA04	pemetrexed	Eli Lilly Nederland B.V.	lug-15	14-set-15	30-ott-15	16-nov-15	044510016	1
PEMETREXED LILLY	EMEA/H/C/4114	L01BA04	pemetrexed	Eli Lilly Nederland B.V.	lug-15	14-set-15	30-ott-15	16-nov-15	044510028	2
PEMETREXED SANDOZ	EMEA/H/C/4011	L01BA04	pemetrexed	Sandoz GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044511018	1
PEMETREXED SANDOZ	EMEA/H/C/4011	L01BA04	pemetrexed	Sandoz GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044511020	2
PEMETREXED SANDOZ	EMEA/H/C/4011	L01BA04	pemetrexed	Sandoz GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044511032	3
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500015	1
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500027	2
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500039	3
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500041	4
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500054	5
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500066	6
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500078	7
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500080	8
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500092	9
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500104	10
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500116	11
PRALUENT	EMEA/H/C/3882	Pending	alirocumab	Sanofi-Aventis groupe	lug-15	23-set-15	30-ott-15	16-nov-15	044500128	12
RAXONE	EMEA/H/C/3834	Pending	idebenone	Santhera Pharmaceuticals (Deutschland) GmbH	lug-15	08-set-15	30-ott-15	16-nov-15	044505016	1
VIAGRA	EMEA/H/C/202/N/88	G04BE03	sildenafil	Pfizer Limited	lug-15	NA	30-ott-15	16-nov-15	034076240	24

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 17/11/2015

VIAGRA	EMA/H/C/202/N/88	G04BE03	sildenafil	Pfizer Limited	lug-15	NA	30-ott-15	16-nov-15	034076253	25
ZALVISO	EMA/H/C/2784/	pending	Sufentanil	Grünenthal GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044514014	1
ZALVISO	EMA/H/C/2784/	pending	Sufentanil	Grünenthal GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044514026	2
ZALVISO	EMA/H/C/2784/	pending	Sufentanil	Grünenthal GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044514038	3
ZALVISO	EMA/H/C/2784/	pending	Sufentanil	Grünenthal GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044514040	4
ZALVISO	EMA/H/C/2784/	pending	Sufentanil	Grünenthal GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044514053	5
ZALVISO	EMA/H/C/2784/	pending	Sufentanil	Grünenthal GmbH	lug-15	18-set-15	30-ott-15	16-nov-15	044514065	6
ZERBAXA	EMA/H/C/3772	J01DI54	ceftolozane / tazobactam	Merck Sharp & Dohme Limited	lug-15	18-set-15	30-ott-15	16-nov-15	044506018	1

La responsabilità di qualsiasi onere e/o attività che l'Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all'immissione in commercio del medicinale, è totalmente a carico dell'Azienda stessa. L'ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.